Published online May 1, 2006
PEDIATRICS Vol. 117 No. 5 May 2006, pp. S261-S269 (doi:10.1542/10.1542/peds.2005-2633E)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feuchtbaum, L.
Right arrow Articles by Cunningham, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feuchtbaum, L.
Right arrow Articles by Cunningham, G.
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SUPPLEMENT ARTICLE

California's Experience Implementing a Pilot Newborn Supplemental Screening Program Using Tandem Mass Spectrometry

Lisa Feuchtbaum, DrPH, MPHa, Fred Lorey, PhDa, Lisa Faulkner, PhDb, John Sherwin, PhDc, Robert Currier, PhDa, Ajit Bhandal, PhDc and George Cunningham, MD, MPHa

a Genetic Disease Branch
c Genetic Disease Laboratory, California Department of Health Services, Richmond, California
b Public Health Institute, Berkeley, California

OBJECTIVE. In response to a California legislative mandate, a pilot tandem mass spectrometry (MS/MS) screening program was undertaken by the Genetic Disease Branch of the California Department of Health Services between January 2002 and June 2003. This article outlines the Genetic Disease Branch approach to implementing the MS/MS pilot program and the program evaluation strategies used.

METHODS. Through the use of multiple data collection methods, we were able to describe hospital participation patterns, screening test uptake, screening test performance, follow-up services utilization, and provider and family satisfaction with the educational materials and follow-up services provided.

RESULTS. During the 18-month pilot program, just more than one half of California's 755698 newborns were offered MS/MS screening; among this group, 90% of parents chose to have their newborns screened. Fifty-one newborns were identified with MS/MS-detectable disorders, among 461 patients referred for follow-up testing (0.13% of the screened population). One disorder was diagnosed successfully for every 6939 newborns screened and for every 9 infants referred (excluding phenylketonuria). The overall California population prevalence of MS/MS-detectable disorders was 1 case per 6500 infants (excluding phenylketonuria). The positive predictive value for medium-chain acyl-CoA dehydrogenase deficiency was 86.7%, whereas the positive predictive value for short-chain acyl-CoA dehydrogenase deficiency was 21.6%. For a sample from Hawaii, 1 isovaleric aciduria case was detected among 6132 newborns.

CONCLUSIONS. Evaluation of the California MS/MS screening pilot program demonstrated that this technology was effective in identifying additional metabolic disorders. The positive predictive value of screening was particularly good for medium-chain acyl-CoA dehydrogenase deficiency. Overall, patient referral rates were very acceptable. The utility of the program was also demonstrated by positive reviews from patients and providers.

Key Words: newborn screening • tandem mass spectrometry • program implementation

Abbreviations: MS/MS—tandem mass spectrometry • GDB—Genetic Disease Branch • MSUD—maple syrup urine disease • GDL—Genetic Disease Laboratory • MCADD—medium-chain acyl-CoA dehydrogenase deficiency • SCADD—short-chain acyl-CoA dehydrogenase deficiency • MMA/PA—methylmalonic acidemia/propionic acidemia • 3MCC—3-methylcrotonyl-CoA carboxylase deficiency • VLCADD—very long-chain acyl-CoA dehydrogenase deficiency • GA—glutaric acidemia • LCHADD—long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency

Accepted Dec 27, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
Impact of Expanded Newborn Screening--United States, 2006
JAMA, November 19, 2008; 300(19): 2242 - 2244.
[Full Text] [PDF]

Home page
 PediatricsHome page
D. B. Bailey Jr, D. Skinner, A. M. Davis, I. Whitmarsh, and C. Powell
Ethical, Legal, and Social Concerns About Expanded Newborn Screening: Fragile X Syndrome as a Prototype for Emerging Issues
Pediatrics, March 1, 2008; 121(3): e693 - e704.
[Abstract] [Full Text] [PDF]